Addex Advances Dipraglurant for Brain Injury Recovery, Reports 2025 Financial Results

Key Takeaways

• Addex repositioned dipraglurant mGlu5 NAM for brain injury recovery applications with new Sinntaxis collaboration
• GABAB PAM chronic cough candidate showed robust anti-tussive activity across multiple disease models, advancing toward clinic
• Company regained full rights to phase 2 mGlu2 PAM asset ADX71149 while partner Indivior progressed substance use disorders program

---

Addex Therapeutics Reports Strategic Pipeline Advances in 2025 Financial Update

Addex Therapeutics announced significant progress across its neurology-focused drug pipeline in its full-year 2025 financial results, highlighted by the repositioning of dipraglurant for brain injury recovery and advancement of its GABAB PAM chronic cough program toward clinical trials.

Dipraglurant Finds New Application in Brain Injury Recovery

The Swiss biopharmaceutical company has strategically repositioned dipraglurant, an mGlu5 negative allosteric modulator (NAM), for brain injury recovery applications. This pivot comes alongside a new option and collaboration agreement with Sinntaxis, granting exclusive licensing rights to intellectual property covering mGlu5 NAM use in brain injury recovery.

Dipraglurant previously underwent clinical testing for other neurological conditions, and this repositioning represents Addex’s strategy to maximize the therapeutic potential of its metabotropic glutamate receptor platform.

GABAB PAM Chronic Cough Program Advances

Addex’s GABAB positive allosteric modulator (PAM) for chronic cough demonstrated robust anti-tussive activity across multiple disease models, positioning the candidate for clinical entry. Chronic cough affects millions of patients worldwide, with limited effective treatment options currently available.

The GABAB receptor pathway represents a novel approach to treating chronic cough, potentially offering patients a new mechanism of action compared to existing therapies.

Pipeline Developments and Partnerships

The company regained full rights to ADX71149, a phase 2 mGlu2 PAM asset, providing Addex with complete control over this program’s future development. Meanwhile, partner Indivior successfully advanced the GABAB PAM substance use disorders program, demonstrating the versatility of Addex’s GABAB platform.

Market Implications

These developments position Addex across multiple high-value therapeutic areas including respiratory medicine, neurology, and addiction treatment. The brain injury recovery market represents a significant unmet medical need, while chronic cough affects an estimated 10% of the global population.

Addex’s metabotropic glutamate receptor expertise continues to generate multiple clinical opportunities, with the company maintaining a diversified pipeline approach to maximize commercial potential.

---

Frequently Asked Questions

What is dipraglurant and how does it work for brain injury recovery?

Dipraglurant is an mGlu5 negative allosteric modulator that targets metabotropic glutamate receptors in the brain. For brain injury recovery, it may help modulate glutamate signaling pathways involved in neuroplasticity and healing processes following brain trauma.

When will Addex’s chronic cough treatment be available to patients?

The GABAB PAM chronic cough candidate is advancing toward clinical trials but has not yet entered human testing. Typical drug development timelines suggest patient availability would be several years away, pending successful clinical trials and regulatory approval.

How does Addex’s approach differ from existing chronic cough treatments?

Addex’s GABAB PAM targets a novel mechanism through GABAB receptors, different from current treatments like dextromethorphan or prescription opioids. This approach could potentially offer improved efficacy with fewer side effects for patients with refractory chronic cough.